Hims and Hers, Inc. (NYSE: HIMS) shows strongly bullish signs that begin and end with the stock price action. It reflects ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Real-time index price for Nasdaq Financial 100 Index (IXF), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

When considering a weight loss medication — or any medication — it’s normal to wonder when the effects will kick in.

Real-time index price for S&P Midcap 400 (IDX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Cava Group beat first-quarter profit and sales estimates, but its outlook wasn't as strong as some had anticipated.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Thousands celebrate the rapid results of weight loss injections. But a new analysis reveals a harsh truth few are prepared ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.